Haemonetics Corporation (HAE) Launches PerQseal Elite, Advancing Minimally Invasive Vascular Care [Yahoo! Finance]
Haemonetics Corporation (HAE)
Last haemonetics corporation earnings: 2/4 06:00 am
Check Earnings Report
US:NYSE Investor Relations:
phx.corporate-ir.net/phoenix.zhtml?c=72118&p=irol-irhome
Company Research
Source: Yahoo! Finance
Haemonetics Corporation (NYSE:HAE), a global leader in blood and plasma management technologies, continues to advance healthcare efficiency through innovative medical devices. In 2025, the company launched the PerQseal Elite vascular closure system, receiving European CE Mark approval. This fully bioresorbable, sutureless device is designed for large-bore vascular access sites commonly used in procedures such as transcatheter aortic valve replacement (TAVR) and endovascular aneurysm repair (EVAR). The PerQseal Elite deploys from inside the vessel without leaving residual materials like collagen or metal implants, restoring the vessel to its natural state while improving procedural control. This launch highlights the industry trend toward minimally invasive, bioresorbable devices that enhance patient outcomes and procedural efficiency. Haemonetics Corporation (NYSE:HAE) released its first-quarter fiscal 2026 results on August 7, 2025. The business reported an earnings per share (E
Show less
Read more
Impact Snapshot
Event Time:
HAE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HAE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HAE alerts
High impacting Haemonetics Corporation news events
Weekly update
A roundup of the hottest topics
HAE
News
- Haemonetics (NYSE:HAE) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $88.00 price target on the stock.MarketBeat
- Haemonetics (NYSE:HAE) had its "outperform" rating reaffirmed by analysts at Raymond James Financial, Inc..MarketBeat
- Haemonetics Is Still Undervalued, Even After The Rally [Seeking Alpha]Seeking Alpha
- Haemonetics (NYSE:HAE) had its price target raised by analysts at Barrington Research from $86.00 to $90.00. They now have an "outperform" rating on the stock.MarketBeat
- Haemonetics (NYSE:HAE) had its price target raised by analysts at Needham & Company LLC from $68.00 to $78.00. They now have a "buy" rating on the stock.MarketBeat
HAE
Earnings
- 11/7/25 - Beat
HAE
Sec Filings
- 11/12/25 - Form 4
- 11/6/25 - Form 10-Q
- 11/6/25 - Form 8-K
- HAE's page on the SEC website